Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Maria E. Cantor | F | 56 | - | |
| Harvey J. Berger | M | 74 | 24 years | |
| Raymond T. Keane | M | 65 | 5 years | |
| Pierre F. Dodion | M | 69 | - | |
| Thomas DesRosier | M | 69 | 1 years | |
| Paris Panayiotopoulos | M | 50 | 1 years | |
| David J. McLachlan | M | 86 | 17 years | |
| Alexander Denner | M | 54 | 3 years | |
| Robert A. Dishman | M | 79 | 6 years | |
| Ivana Magovcevic-Liebisch | M | 55 | 12 years | |
| Jules Haimovitz | M | 73 | 1 years | |
| Christophe M. Bianchi | M | 62 | - | |
| Stephen S. Galliker | M | 77 | 9 years | |
| Wayne L. Wilson | M | 75 | 8 years | |
| Keith S. Ehrlich | M | 73 | 1 years | |
| Athanase Lavidas | M | 75 | 13 years | |
| Robert Whelan | M | 72 | 4 years | |
| David L. Berstein | M | 72 | 14 years | |
| Tamara Joseph | F | 61 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 years |
| Norbert Riedel | M | 66 | 6 years | |
| Elona Kogan | F | 54 | 1 years | |
| Yan Moore | M | 58 | 2 years | |
| Sergio Santillana | M | 61 | 1 years | |
| Laurie A. Allen | F | 63 | 9 years | |
| Edward Fitzgerald | M | 68 | 14 years | |
| George Bickerstaff | M | 68 | 1 years | |
| Massimo Radaelli | M | 65 | 8 years | |
| Daniel M. Bollag | M | 63 | 8 years | |
| Manmeet Singh Soni | M | 46 | 1 years | |
| Sarah Schlesinger | M | 64 | 4 years | |
| Doug Treco Treco | M | 66 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 17 years |
| Matthew Ros | M | 57 | 3 years | |
| Jay R. LaMarche | M | 76 | 24 years | |
| Anna Protopapas | F | 59 | 2 years | |
| Obed M. Cepeda | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 years |
| William Shakespeare | M | 60 | 21 years | |
| Mark de Souza | M | - | - | |
| Andreas Woppmann | M | - | - | |
| Chester A. Metcalf | M | - | 15 years | |
| John McCabe | M | 55 | 1 years | |
| Melanie Morel-Ferris | F | 44 | - | |
| Sylvia Cheung | F | 50 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 years |
| Christopher Verni | M | 49 | 2 years | |
| Aaron Sato | M | - | 7 years | |
| Stephen R. Jamieson | M | - | - | |
| Jing Marantz | M | 58 | - | |
| Jayne M. Gansler | F | - | - | |
| Victor Rivera | M | 59 | 24 years | |
| Kelly M. Schmitz | M | - | - | |
| David Kerstein | M | 41 | 3 years | |
| Piet A. M. Vervaet | M | - | - | |
| Adi Mohanty | M | 57 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 years |
| Lori Horvat | F | - | 8 years | |
| Mark Organisak | M | - | 2 years | |
| Jennifer Herron | F | 54 | 1 years | |
| Matthew P. Kowalsky | M | 52 | - | |
| Hugh Cole | M | 59 | 3 years | |
| Elizabeth Hamilton Seabury Wyatt | M | 76 | 6 years | |
| Frank G. Haluska | M | 64 | 9 years | |
| Gregory D. Phelps | M | 75 | 4 years | |
| Mary C. Tanner | F | 73 | - | |
| Gregory Perry | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 years |
| Neil Kirby | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | - |
| Martin Duvall | M | 62 | 5 years | |
| Richard Pascoe | M | 60 | 3 years | |
| Nicholas Ventresca | M | 63 | 2 years | |
| Konstantinos Andrikopoulos | M | 58 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 years |
| Daniel Geffken | M | 67 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 6 years |
| Jonathan Leff | M | 55 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 years |
| James Edward Thomas | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | - |
| Lynn G. Baird | M | 76 | 5 years | |
| Burton E. Sobel | M | 86 | 6 years | |
| Sandy Smith | M | 77 | 17 years | |
| A. Collier Smyth | M | 78 | 2 years | |
| Michael Kishbauch | M | 75 | 4 years | |
| Renato Fuchs | M | 80 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 4 years |
| Camille Bedrosian | M | 71 | 6 years | |
| Joseph Bratica | M | 60 | 22 years | |
| Dave Grayzel | M | 56 | 2 years | |
| John W. Loewy | M | - | - | |
| Paul Brannelly | M | 51 | 3 years | |
| Timothy J. Maines | M | - | 3 years | |
| Virginia R. Dean | F | 58 | - | |
| Ross Pettit | M | - | - | |
| Anthony S. Murabito | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 years |
| Keith Regnante | M | 54 | 1 years | |
| Stephanie Pearl | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 87 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Shirish Hirani
- Personal Network
